Zevra Therapeutics Inc 2024年度报告

FORM10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember 31, 2024 ☐TRANSITION REPORT PURSUANTTO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____ to _____Commission File No.001-36913 Zevra Therapeutics, Inc.(Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section 12(b) of the Act: Table of Contents Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements forthe past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(§ 232.405 of this chapter)during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” inRule 12b-2 of the Exchange Act.: Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerginggrowth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by anyof the registrant's executive officers during the relevant recovery periodpursuant to§ 240.10D-1(b).☐ Indicate by check mark whetherthe registrantisashell company (asdefinedin Rule12b-2of the Exchange Act). Yes☐No☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 28, 2024, the last business day of theregistrant’s most recently completed second fiscal quarter, was approximately $204.8million, based upon the closing sales price for the registrant’s commonstock, as reported on the Nasdaq Global SelectMarketon June 28, 2024. The calculation of the aggregate market value of voting and non-voting common equityexcludes shares of common stock the registrant held by executive officers, directors and stockholders that the registrant concluded were affiliates of the registranton that date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause thedirection of management or policies of the registrant or that such person is controlled by or under common control with the registrant. As ofMarch 7, 2025, the registrant had54,115,869shares of common stock outstanding. Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to its 2025annual meeting of stockholders are incorporated by reference into Part III of this AnnualReport on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of thefiscal year to which this report relates. Table of Contents ZEVRA THERAPEUTICS, INC.FORM 10-K PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases ofEquity SecuritiesItem 6.[Reserved]Item 7.Management's Discussion and Analysis of Financial Condition and Resultsof OperationsItem 7A.Quantitative and Qualitative Disclosures About Market RiskItem 8.Financial Statements andSupplementary DataItem 9.Changes in and Disagreements With Accountants on Accounting and Financial DisclosuresItem 9A.Controls and ProceduresItem 9B.Other InformationItem 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspec